The HUM project is a collaborative RD project involving an academic partner: INSERM through Unit 1297, the ESTER ‘Vascular, Metabolic and Endocrine Dysfunctions’ team located in Toulouse, and two industrial partners: PhysioStim, a small company headquartered in Castres (81), specialising in the cardiovascular pharmacology of medicines, MT-act, a CNRS spin-off biotechnology company, which designs and develops new molecules for therapeutic purposes to meet a growing and still unsolved demand for the treatment of age-related diseases. The objective of this project is to develop a platform entirely based on human tissue, taking into account the aging, sex and pathology of the donor. This platform will serve as an essential link between preclinical studies and clinical trials. Its goal is to improve predictability, significantly reduce development costs and risks, while accelerating the time-to-market of molecules.